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CASE REPORT
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Known ocular manifestations of Alport syndrome include features such as
anterior lenticonus and fleck retinopathy. Reports of keratoconus in such patients
are limited. We report tomographic findings consistent with keratoconus in a
patient with Alport syndrome.
CASE SUMMARY
A 52-year-old female was referred to our ophthalmology clinic with decreased
vision and increased tearing. She was diagnosed with stage III Alport syndrome
two years prior. Upon examination she was found to have average keratometries
of 48 D bilaterally with tomographic evidence of keratoconus.
CONCLUSION
Although a rare presentation, concurrent Alport syndrome and keratoconus
should be considered when reviewing the ocular health of Alport syndrome
patients and appropriate management steps should be taken upon the diagnosis.
Key words: Alport syndrome, Keratoconus; Type IV collagen; COL4A genes; Corneal
ectasia; Case report
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Core Tip: Various ocular manifestations of Alport syndrome have been well described.
However, reports of keratoconus in the presence of Alport syndrome is limited in the
literature. Keratoconus is a form of corneal ectasia and has shown disorganized and
thinning collagen under microscopy. Both Alport syndrome and keratoconus
demonstrate collagenous changes which may eventually lead to impaired function of the
affected tissue. We present a case of keratoconus in the presence of Alport syndrome.
Citation: Moshirfar M, Skanchy DF, Gomez AT, Ronquillo YC, Buckner B, Hoopes PC.





Alport syndrome is an inherited disease characterized by progressive renal disease,
hearing loss, and ocular abnormalities. It was first described as “familial congenital
haemorrhagic nephritis” by Arthur Cecil Alport in 1927[1]. Inherited genetic mutations
of COL4A5 (X-linked), COL4A3 and COL4A4 (autosomal recessive) produce defects in
the alpha chains that form type IV collagen[2,3]. Type IV collagen is a component of
basement membranes throughout the body[4]. Specifically, the heterotrimer α3α4α5
plays  a  crucial  role  in  the  glomerular  basement  membrane  of  the  kidney,  stria
vascularis of the cochlea, Descemet’s membrane and Bowman’s layer of the cornea,
lens capsule, and both the inner limiting membrane and Bruch’s membrane of the
retina[5].  The most  common ocular  manifestations  in  Alport  patients  are  corneal
opacities,  anterior  lenticonus,  cataract,  fleck  retinopathies,  and temporal  retinal
thinning[5]. The prevalence of the disease has been estimated around 1:10000 with the
X-linked variant accounting for 85% of the disease[6].
Keratoconus is a corneal dystrophy resulting in corneal ectasia due to central or
paracentral stromal thinning[7]. The pathophysiology is poorly understood, but breaks
in Bowman’s layer, collagen disorganization, and scarring have all been described.
Although the etiology remains unknown, both genetic and environmental factors,
such as eye rubbing, are believed to contribute to the disease process. Keratoconus has
a  known  association  with  Down  syndrome,  Leber’s  congenital  amaurosis,  and
connective tissue diseases such as Ehler’s Danlos[8].
Despite the wide variety of ocular manifestations found in patients with Alport
syndrome, corneal ectasia appears to be a rare finding. The literature is limited on the
presence  of  keratoconus  in  these  patients[9].  We  report  an  interesting  case  of
tomographic findings consistent with keratoconus in a patient with Alport syndrome.
CASE PRESENTATION
Chief complaints
A 52-year-old female was referred to our ophthalmology clinic with decreased vision
and increased tearing.
History of present illness
She  was  diagnosed  with  stage  III  Alport  syndrome  two  years  prior  which  was
currently stable per her nephrologist. During these two years had gradual decline in
her visual acuity that was not correctable to 20/20.
History of past illness
She had a past medical history of asthma, diabetes mellitus, and hypertension.
Family history
Family history was positive for Alport  syndrome in her mother and brother but
without any known ocular or hearing abnormalities.
Physical examination
On initial examination (Table 1), uncorrected distance visual acuity was 20/60 on the
right and 20/30 on the left, with a corrected visual acuity of 20/30 bilaterally.
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Table 1  Parameters from the patient’s initial and follow-up encounters
Encounter Initial encounter 2 mo follow up Initial encounter 2 mo follow up
Eye OD OD OS OS
Vision Acuity
UDVA 20/60- 20/60 20/30- 20/40
BCVA 20/30 20/25-2 20/30 20/25+
Man. Refraction -1.50-1.75 x 031 -0.75-2.25 x 037 -1.00-2.75 x 149 -0.75-3.75 x 147
Tomography
Front
K1 (flat) 47.0 D 46.7 D 47.1 D 47.1 D
K2 (steep) 48.9 D 49.5 D 49.6 D 50.1 D
Km 47.9 D 48.1 D 48.3 D 48.5 D
Axis 31.0° 36.1° 146.4° 148.7°
Back
K1 -6.5 -6.5 -6.7 -6.7
K2 -6.9 -6.9 -6.9 -7.0
Km -6.7 -6.7 -6.8 -6.8
Axis 40.3° 53.6° 123.9° 134.2°
Pachymetry
Pupil center 506 μm 502 μm 474 μm 472 μm
Pachy apex 505 μm 499 μm 472 μm 463 μm
Thinnest 496 μm 489 μm 454 μm 448 μm
UDVA: Uncorrected distance visual acuity; BCVA: Corrected distance visual acuity; Km: Mean keratometry.
Slit  lamp  examination  showed  bilateral  eyelid  laxity,  papillary  conjunctival
changes, prominent nerves, superficial punctate keratitis, unilateral (OD) anterior
basement  membrane changes,  with no guttata,  apical  scarring,  or  corneal  striae.
Dilated fundus exam revealed bilateral floaters in the vitreous humor and normal
retinal vasculature.
Imaging examinations
Initial Pentacam (Oculus, Wetzlar, Germany) tomography revealed mean keratometry
of 47.9 D in the right and 48.3 D in the left, with a 2 mo follow-up scan revealing a
mean keratometry of 48.1 D and 48.5 D respectively (Table 1). During this 2 mo period
progressive corneal thinning occurred bilaterally. There was also bilateral anterior
curvature steepening with no appreciable changes in the posterior curvature.
FINAL DIAGNOSIS
Average  keratometries  above  47  to  48  D  have  been  shown  to  correlate  with
keratoconus[10,11]. Based on the Amsler-Krumeich Classification system our patient was
diagnosed with stage 2 keratoconus, with signs of progression over two months,
including further corneal thinning and increased steepening. the disease[12,13]. This
diagnosis  was  reinforced  with  the  Pentacam Belin/Ambrosio  Enhanced Ectasia
Display which highlights tomographic abnormalities consistent with keratoconus
(Figure 1).
TREATMENT
Although no curative  treatment  is  available  for  patients  with  Alport  syndrome,
Angiotensin-converting  enzyme  inhibitors,  angiotensin  receptor  blockers,  and
aldosterone inhibitors reduce stress on the kidneys and may slow the progression of
renal  failure[14,15].  Yearly  hearing and vision tests  are  recommended for  patients
diagnosed with Alport syndrome from the time the patient is 7 or 8 years old[14].
Ophthalmologic manifestations of Alport syndrome are treated symptomatically,
including lens removal and intraocular lens placement for lenticonus and cataract.
Our patient was advised to continue to use glasses and avoid eye rubbing.
WJCC https://www.wjgnet.com October 6, 2019 Volume 7 Issue 19
Moshirfar M et al. Keratoconus with Alport syndrome
3014
Figure 1
Figure 1  Pentacam Belin/Ambrosio enhanced ectasia display highlighting abnormal values of deviation of front elevation difference map, deviation of
back elevation difference map, deviation of average pachymetric progression, deviation of minimum thickness, deviation of Ambrosio relational thickness
(ART max), and total deviation. A: Initial examination of right eye; B. 2 Mo follow-up of right eye; C: Initial examination of left eye; D: 2-Mo follow-up of left eye. Df:
Deviation of front; Db: Deviation of back; Dp: Deviation of average pachymetric; Dt: Deviation of minimum thickness; Da: Deviation of Ambrosio; D: Total deviation.
OUTCOME AND FOLLOW-UP
While  her  keratoconus was mild,  continued signs  of  disease  progression would
warrant  discussion  of  corneal  collagen  crosslinking  while  reserving  corneal
transplantation for advanced disease.
DISCUSSION
The concurrent presentation of Alport syndrome and keratoconus, to our knowledge,
has only been described once in the literature. Chugh et al[9]  reported that 3 of 45
(6.7%) patients  diagnosed with Alport  syndrome were found to have associated
keratoconus. This is the first report in the literature of tomographic findings consistent
with keratoconus in a patient with Alport syndrome. While the inheritance patterns
for Alport syndrome are well defined, the inheritance of keratoconus is under much
investigation. Variants of the COL4A3 and COL4A4 genes are two of many possible
genetic causes of keratoconus[16-18].  One study found that seven polymorphisms of
COL4A3 and COL4A4 were associated with keratoconus, although no mutations were
directly  linked  with  the  disease[17].  A  meta-analysis  of  genetic  associations  for
keratoconus concluded that COL4A4 had differential effects on keratoconus between
ethnic groups[18]. Specific mutations of the COL4A3 and COL4A4 genes are known to
cause of Alport syndrome.
A  range  of  kidney-related  diseases  including  chronic  renal  failure,  kidney
transplant,  hypertension,  diabetes  mellitus,  and various  medications  have  been
associated with  keratoconus[19].  One theory is  that  both renal  and ocular  tissues
express  the  PAX6  gene.  PAX6  is  linked  to  corneal  gelatinase  B,  which  is  a
metalloprotease responsible for corneal structure regulation. Thus, a mutated PAX6
gene may contribute to keratoconus and renal pathology[19]. Aldave et al[20] reported
cases of polymorphous corneal dystrophy (PPCD) in Alport patients[5]. However, the
process of corneal steepening found in PPCD is likely independent from that found in
keratoconus,  as  the  steepening often  presents  with  the  absence  of  other  clinical
features of keratoconus.
In  Alport  syndrome,  the  normal  collagen  IV  α3α4α5  network  is  lost  and  the
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immature α1α1α2 network persists. This α1α1α2 network has fewer crosslinks and
more proteolytic cleavage sites. This produces basement membranes that are more
susceptible  to  biomechanical  strain.  It  also  induces  an  increase  in  matrix
metalloprotease activity[5].  Increased activity of protease enzymes and decreased
protease inhibitors have been found in keratoconus[11]. Disorganization of collagen
fibrils  and  a  diminished  number  of  crosslinks  within  and  between  such  fibrils
contributes to the weakened biomechanical  state of  the cornea in keratoconus[21].
Increased protease activity and decreased crosslinking may be a possible connection
between the two diseases.
Further studies are necessary to elucidate the underlying molecular mechanisms
possibly linking keratoconus and Alport syndrome. One of the limitations of this
report is an absence of genetic testing. We were unable to obtain sequencing and
analysis of the patient’s exome or genome. These tests would have the potential to
reveal specific genetic mutations leading to Alport syndrome in this patient and a
more definitive link to keratoconus. When obtained, these tests will provide much
value.
CONCLUSION
Although a rare presentation, concurrent Alport syndrome and keratoconus should
be considered when reviewing the ocular health of Alport syndrome patients and
appropriate management steps should be taken upon the diagnosis.
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